Treatment with homoharringtonine and cytarabine in patients with high risk acute myelogenous leukemia (AML).

被引：0
|
作者：
Chang, Naibai [1 ]
Wei, Jianping [1 ]
Zhao, Shengming [1 ]
Liu, Hui [1 ]
Fan, Yun [1 ]
Li, Jiangtao [1 ]
Xu, Xiaodong [1 ]
Gu, Xichun [1 ]
机构：
[1] Beijing Union Med Coll Hosp, Dept Hematol, Beijing, Peoples R China
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4555
引用
收藏
页码：218B / 218B
页数：1
相关论文
共 50 条
  • [41] Venetoclax Combining with Homoharringtonine,Daunorubicin and Cytarabine (HAD) As Induction Treatment in Newly Diagnosed Adult Acute Myeloid Leukemia Patients
    Yan, Zhangsong
    Li, Yang
    Zhang, Bin
    He, Jinsong
    Li, Jiesi
    Wei, Shuning
    Wang, Qi
    Li, Qiuling
    Hu, Bo
    Liu, Kaiqi
    Mi, Yingchang
    BLOOD, 2023, 142
  • [42] IDARUBICIN PLUS CONTINUOUS-INFUSION HIGH-DOSE CYTARABINE AS TREATMENT FOR PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA OR MYELODYSPLASTIC SYNDROME
    ESTEY, EH
    KANTARJIAN, H
    KEATING, M
    SEMINARS IN ONCOLOGY, 1993, 20 (06) : 1 - 5
  • [43] FMS EXPRESSION, FRATRICIDE, AND TREATMENT OUTCOME IN ACUTE MYELOGENOUS LEUKEMIA (AML)
    HEGDE, U
    HANDA, H
    BRAUN, D
    RAZA, A
    GREGORY, S
    LARSON, R
    PREISLER, HD
    BLOOD, 1994, 84 (10) : A619 - A619
  • [44] Homoharringtonine with low dose cytarabine combination therapy induces both hematologic and cytogenetic remissions in patients with chronic myelogenous leukemia
    Ernst, TJ
    Soiffer, R
    Stone, R
    Farber, D
    BLOOD, 1996, 88 (10) : 2300 - 2300
  • [45] CYTARABINE INDUCED SKIN ERUPTION IN ACUTE MYELOGENOUS LEUKEMIA
    Abbassi, S.
    Kuster, J.
    Wolff, A.
    Capitle, E.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2019, 123 (05) : S66 - S66
  • [46] Carboplatin plus cytarabine in the treatment of high-risk acute myeloblastic leukemia
    Larrea, L
    Martínez, JA
    Sanz, GF
    Martín, G
    de la Rubia, J
    Jiménez, C
    Jarque, I
    Cid, A
    López, A
    Sanz, MA
    LEUKEMIA, 1999, 13 (02) : 161 - 165
  • [47] Carboplatin plus cytarabine in the treatment of high-risk acute myeloblastic leukemia
    L Larrea
    JA Martínez
    GF Sanz
    G Martín
    J de la Rubia
    C Jiménez
    I Jarque
    A Cid
    A López
    MA Sanz
    Leukemia, 1999, 13 : 161 - 165
  • [48] Tipifarnib in combination with idarubicin and cytarabine in patients with newly diagnosed acute myeloid leukemia (AML) or high risk myelodysplastic syndrome (MDS).
    Ravandi-Kashani, F.
    Kantarjian, H.
    Garcia-Manero, G.
    O'Brien, S.
    Verstovsek, S.
    Estrov, Z.
    Faderl, S.
    Giles, F.
    Wright, J.
    Cortes, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 351S - 351S
  • [49] Phosphoprotein mapping of acute myelogenous leukemia (AML)
    Sjoholt, G.
    Hovland, R.
    Fladmark, K. E.
    Abraharnsen, J. F.
    Bruseudog, O.
    Gjertsen, B. T.
    MOLECULAR & CELLULAR PROTEOMICS, 2004, 3 (10) : S48 - S48
  • [50] Cytoprotection in acute myelogenous leukemia (AML) therapy
    Grosso, D
    Filicko, J
    Garcia-Manero, G
    Beardell, F
    Brunner, J
    Cohn, J
    Ferbér, A
    Martinez, J
    Mookerjee, B
    Rose, L
    Tice, D
    Wagner, JL
    Capizzi, R
    Flomenberg, N
    SEMINARS IN ONCOLOGY, 2004, 31 (06) : 67 - 73
12345